Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sizing Up The Competition In BTK Inhibition

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Celgene’s latest Phase I dose-ranging data for the BTK inhibitor CC-292 show better response rates than before. The BTK target has become highly attractive, yet the competitive landscape for this particular class still looks sparse, with four drugs in the clinic and two slated for INDs in 2014.

Advertisement

Related Content

CLL Sponsors Look To Create Winning Combinations
CLL Serves As Springboard To Mass Of Lymphoma Markets
Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline
Pharmacyclics’ Ibrutinib Scoops Another FDA Breakthrough Designation, And Pfizer Joins The Club
Ibrutinib Results Suggest Potential To Shake Up CLL Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS005426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel